Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

NRAMP1 is not associated with asthma, atopy, and serum immunoglobulin E levels in the French Canadian population


Reduced infection by mycobacteria, including Mycobacterium tuberculosis, may be partly responsible for increased prevalence of allergic and autoimmune diseases in developed countries. In a murine model of innate resistance to mycobacteria, the Nramp1 gene has been shown to affect asthma susceptibility. From this observation, it was proposed that human NRAMP1 may be a modulator of asthma risk in human populations. To experimentally test the candidacy of NRAMP1 in asthma susceptibility, we characterized five genetic variants of NRAMP1 (5′CAn, 274C>T, 469+14G>C, D543N, and 1729+del4) in an asthma family-based cohort from northeastern Quebec. We did not observe any significant association between NRAMP1 variants (either allele or haplotype specific) with asthma, atopy, or serum immunoglobulin E levels. These results demonstrate that, in spite of direct involvement of Nramp1 in a murine asthma model, in human populations NRAMP1 is not likely to be a major contributor to the genetic etiology of asthma and asthma-related phenotypes.


In 1989, David Strachan reported the findings of a prospective study of 17 414 British children from birth to 23 years of age.1 The study found a significant inverse correlation between the number of older siblings in the household and the prevalence of hay fever at age 11 and 23 years. A similar correlation was also observed for eczema in the first year of life. Subsequent epidemiologic studies confirmed the inverse association between family size and atopic markers such as skin prick positivity and specific immunoglobulin (Ig) E titers.2 To explain the inverse correlation between family size and atopy, it was suggested that declining family size, improved household amenities, and higher standards of personal cleanliness, all associated with improved hygiene, had reduced the opportunities of cross-infection, and this may have increased the prevalence of atopic diseases. This explanation is now known as the hygiene hypothesis and it has been extended to include autoimmune diseases in general.

One proposed mechanism underlying the hygiene hypothesis is that microbial exposures to viruses, bacteria, and parasites elicit an immune response towards the maturation of T helper type 1 cells (Th1), and the subsequent production of cytokines such as interleukin (IL)-2 and interferon-γ. This predominating Th1 immune response suppresses the production of Ig E and IgG1, as well as cytokines IL4, IL5, IL9, and IL13, characteristic of type 2 (Th2) responses. The possibility of a Th1/Th2 imbalance and an association between Mycobacterium tuberculosis infection and atopy expression was first shown by a study of Japanese school children.3 The study reported an inverse association between delayed hypersensitivity to tuberculin, a broad measure of exposure to mycobacteria (Th1 response), and serum IgE levels (Th2 response), and concluded that exposure to M. tuberculosis may inhibit the development of atopic diseases. In humans, M. tuberculosis is the cause of tuberculosis (TB). However, not all individuals exposed to M. tuberculosis will become infected, and of those infected only a small proportion will develop clinical disease.4, 5 It is now well established that both genetic and environmental factors determine the progression from exposure to infection and from infection to disease. If M. tuberculosis infection protects against atopy, then genetic risk factors for TB susceptibility may be protective for asthma and vice versa. A well-established TB susceptibility gene is the natural resistance associated macrophage protein 1 gene (NRAMP1). In addition to its known role in TB susceptibility, its associations with numerous immune-mediated disorders such as rheumatoid arthritis, type I diabetes, and multiple sclerosis are making NRAMP1 a prime candidate to test the hypothesis of inverse genetic control of asthma and TB susceptibility.6, 7

Data from the mouse support the candidacy of NRAMP1 as an asthma susceptibility gene. It has been shown that Nramp1-resistant (Nramp1r) mice have a lower IgE and IL-4 response compared to Nramp1-susceptible (NRAMP1s) mice after infection with an attenuated strain of Salmonella typhimurium,8 demonstrating that Nramp1 can modulate Th1/Th2 host responsiveness. Moreover, in M. vaccae and allergen-sensitized mice, subsequent allergen challenge triggered higher levels of Th2 cytokines (IL-4, IL-5, IL-13) and IgE in Nramp1s as compared to Nramp1r mice.9 This finding implies that the ability to develop atopy-associated Th2 responses is dependent on susceptibility to infection, dictated in this model by Nramp1. Finally, M. vaccae is more efficient in lowering allergic and asthmatic symptoms in allergen-challenged Nramp1s than in Nramp1r mice,10 directly demonstrating that Nramp1 can modify immune responses following mycobacterial infection. Taken together, these observations provide a direct experimental link between genetically controlled resistance to infection and altered asthma susceptibility, and constitute the main motivating force for the present study.


Patient characteristics

Clinical characteristics of the study participants have been reported previously.11 Briefly, 1139 individuals between ages 3 and 88 years were recruited. The median age of onset for index cases and their affected siblings is 5 years (2–46 years). Of the 570 subjects with asthma and 569 without asthma, 419 (74%) and 218 (38%) were atopic, respectively. The male to female ratios in probands, affected and unaffected family members are 1 : 1.2, 1 : 1.4, and 1 : 1.2, respectively. Index cases have higher IgE levels and coexistence of atopy compared to other affected family members.

Genetic variants of the NRAMP1 locus

We characterized five polymorphisms of the NRAMP1 gene in the family-based cohort (Figure 1). Variant 5′(CA)n is a promoter dinucleotide repeat polymorphism; variant rs2276631 (reference SNP identifier from the National Center for Biotechnology Information database) is a synonymous C>T polymorphism in exon 3 (common alias 274 C>T); rs3731865 involves a G>C base change in intron 4 (common alias 469+14G>C); variant D543N is a G>A substitution resulting in an aspartic acid to asparagine amino-acid change in exon 15, and variant 1729+55del4 is a TGTG tetranucleotide deletion polymorphism in the 3′ untranslated region (Table 1). All variants have previously been described.32 NRAMP1 variants were selected due to their known associations with susceptibility to infectious and autoimmune diseases. In the French–Canadian families, variants in the 5′ NRAMP1 region (5′(CA)n, 274C>T, and 469+14G>C) are polymorphic, with minor allele frequencies of 0.31, 0.28, and 0.31, respectively, and all variants are in Hardy–Weinberg equilibrium. Variants 1729+del4 and D543N were uninformative (minor allele frequency = 0.012 and 0.017, respectively). Hence, these two 3′ end variants were not further analyzed.

Figure 1

Chromosomal location of NRAMP1 polymorphisms associated with common diseases. In the schematic presentation of the NRAMP1 genomic organization, exons are depicted as black boxes with the corresponding exon numbers on top. Introns are depicted as lines between exon boxes. Genomic distances between exons are indicated by the scale in kilobases (kb) above the panel, with 0 kb being the transcription start site of exon 1 and 13.6 kb indicating the end of exon 15. The white box 4a represents the alternatively spliced exon 4A.10 Positions of variants are indicated by arrows. Names or identification numbers of variants are given underneath the arrows.

Table 1 NRAMP1 polymorphisms and disease associations

Family-based association analysis of NRAMP1 with asthma, atopy, and IgE levels

The three informative NRAMP1 polymorphisms located in the 5′ region of the gene were tested individually for association with asthma, atopy, and IgE levels (Table 2). IgE serum levels were analyzed as dichotomous trait, independent of atopy status. Subjects were classified either as high or low responders according to their IgE levels. Based on the normal distribution of the log (IgE) values, a cutoff point of 100 mg/l divided the subjects into low (two-thirds of participants) and high (one-third) responders. We tested allelic associations under additive and dominant genetic models. No allele was significantly (P<0.05) transmitted nonrandomly to offspring with asthma or atopy, or to high IgE responders. The 469+14G allele, under an additive model, was nonsignificantly overtransmitted to asthmatic offspring (P=0.08).

Table 2 Allele transmission pattern for asthma and related phenotypes

Haplotype-specific association analysis

Association among the three variants was assessed by measuring pairwise linkage disequilibrium (LD) using D′. The three variants are strongly associated, as evidenced by a high degree of LD (D′>0.90) among them (data not shown). Alleles of the three variants are likely to be transmitted together as groups, or haplotypes. Within this region of high LD, two haplotypes with frequency >0.1 are observed: haplotype (5′(CA)n) allele 3-(274)C-(469+14)G (frequency=0.683) and haplotype allele 2-T-C (0.258). Other less frequently occurring haplotypes are allele 2-C-G (0.021), allele 2-C-C (0.015), and allele 3-C-C (0.010). All haplotypes were assessed for nonrandom transmissions in the asthma families using family-based association testing software (FBAT), version 1.533, 34 (Table 3). Under additive and dominant genetic models, all haplotypes were randomly transmitted to offspring with either asthma, atopy, or high IgE responsiveness.

Table 3 Haplotype transmission pattern of NRAMP1

Power calculations

We examined the possibility that the failure to detect association of NRAMP1 variants with asthma and related phenotypes was due to insufficient power of the study sample. Power was calculated for 60 sets of parameters defined by susceptibility allele frequency (q) and genetic attributable fraction (GAF) for an additive disease model with disease prevalence set at 0.10 (Figure 2). The result shows that with the present cohort of 1139 individuals there is excellent power (>80%) to detect variants across a wide allele frequency range (0.20–0.50) for a heterozygotes odds ratio (HET OR) >1.6. For example, for q=0.20, power >80% is achieved with GAF ≥0.20, corresponding to a HET OR >1.6 (Figure 2). For the low allele frequencies of 0.05 and 0.10, power >80% is achieved for a HET OR >1.8. For the high allele frequency of 0.70, power >80% is achieved for a HET OR >1.7 (data not shown). By contrast, power to detect variants with a HET OR <1.4 is poor (<60%) for the allele frequency range of 0.10–0.70, although such small-risk modifiers may still account for a substantial proportion of cases, especially if the risk variant is present at high allele frequencies. For low allele frequencies <0.05, power is poor even for a HET OR between 1.6 and 1.8. Overall, the results of the power calculation argue against NRAMP1 alleles being asthma susceptibility factors with relative risk >1.8 in the French Canadian population.

Figure 2

Power estimates. The GAF of a susceptibility allele is plotted on the x-axis against power to detect association on the y-axis. Susceptibility allele frequencies (q) of 0.05, 0.1, 0.2, 0.3, 0.5, and 0.7 are tested. Each line of squares corresponds to the power calculated under an additive disease model with disease prevalence of 0.10, for a specific q across a range of GAF. The color of the squares represents the associated odds ratios of the heterozygotes (HET OR), according to the color gradient on the right of the graph. A heterozygote odds ratio of 2 indicates that an individual with one copy of the susceptibility allele has twice the risk to develop the disease as does a person with no copy of the susceptibility allele. For example, if the susceptible allele of frequency 0.30 attributes to 25% of the cases (GAF=0.25), and exerts a HET OR between 1.6 and 1.8 (light blue), then the present cohort has power >0.80 (80%) to detect the association between allele and disease.


In light of the hygiene hypothesis and the Th1/Th2 paradigm in TB and asthma pathogeneses, the established TB susceptibility gene, NRAMP1, is a strong candidate gene for asthma susceptibility. In mice, the Nramp1 gene encodes a 90–100 kDa transmembrane protein and its mRNA is expressed in primary macrophages and granulocytes. The Nramp1 protein is found at the late endosomal/lysosomal compartment of macrophages.35, 36 Nramp1 is a major determinant of innate host resistance to infection. The gene affects intracellular replication of a wide range of pathogens including S. typhimurium,37 Leishmania donovani,38 M. lepraemurium,39 M. intracellulare,40 M. avium,41 and the TB vaccine strain M. bovis — Bacillus Calmette-Guérin (BCG).42 Specifically, a glycine-to-aspartic-acid change at amino acid 169 (G169D), located in the predicted transmembrane domain number 4 (TM 4), has removed the host's ability to inhibit pathogen growth.43, 44 Comparative sequence analysis of the Nramp gene family suggested that Nramp1 functions as a divalent cation transporter.45 Kinetic studies demonstrated that Nramp1 transports cations out of the phagosomes, and, consequently, mediates depletion of nutrients potentially essential for survival of pathogens in the host cell phagosome.46, 47 In addition, Nramp1 is critical to overcome pathogen-triggered blockages of intracellular vesicle trafficking.48 The exact function of human NRAMP1 is not known. However, due to its high sequence homology with mouse Nramp1 (93% overall sequence similarity and 88% sequence identity), the NRAMP1 protein is likely to be a divalent cation transporter.49, 50, 51, 52, 53 The amino-acid sequences of Nramp1 and NRAMP1 in predicted TM 4 are identical, but the homologous G169D variant in TM 4 has not been found in human NRAMP1.49 However, genetic variants at the 5′ and 3′ ends of the human gene are associated with infectious and autoimmune disease susceptibility.6, 7

Based on the previous findings in a murine model of asthma demonstrating that the propensity to mount an atopic immune response is dependent on Nramp1, we carried out a family-based association study to test if, in humans, NRAMP1 genetic variants are associated with asthma and related phenotypes, such as atopy and IgE levels. We selected five NRAMP1 variants that had previously been shown to be associated with susceptibility to a variety of immune disorders and infectious diseases (Table 1). Specifically, polymorphisms in the 5′ region of NRAMP1 have been found to be risk modifiers for TB in multiple populations. This suggests that a variant located in the 5′ NRAMP1 region impacts on NRAMP1 function. The 5′(CA)n promoter variant has been linked to variable NRAMP1 mRNA expression.54, 55 Promoter allele 3 drives a higher mRNA expression compared to other alleles such as allele 2 (Table 1) in the absence of any stimulant. When stimulated with interferon-γ, alleles 2, 3, and other rare alleles demonstrate enhanced mRNA expression. When co-stimulated with interferon-γ and bacterial antigen lipopolysaccharide, expression by allele 2 is reduced, while that of allele 3 is further enhanced.54 Interestingly, allele 3 has been found to be associated with TB protection, and with risk for type I diabetes, an autoimmune disorder.6

Despite supportive evidence from a mouse model of atopic disease, we failed to detect an impact of human NRAMP1 on asthma and related phenotypes. Our findings suggest that NRAMP1 genetic variants do not play a major role in human atopic disease. Detailed power calculation indicated that our cohort is of sufficient size (power >80%) to detect associations of allelic variants with weak impact on disease risk (HET OR >1.6). However, cohort size is insufficient (power <60%) to detect variants with very low impact on disease risk (HET OR <1.4). The inability to detect genetic risk factors with such low impact on disease risk is not unique to the present study. Due to unfavourable cost–benefit ratios, genetic studies are rarely powered to detect risk variants with OR <2.

The reason why we could not replicate the mouse findings in a human population is unknown. However, it is becoming increasingly clear that the majority of common human diseases are multifactorial and complex, and that animal systems might not be able to accurately model all aspects of human diseases. In the case of NRAMP1, differences between the mouse model of innate resistance/susceptibility to mycobacteria and human mycobacterial diseases are well known. In mice, Nramp1 controls intracellular replication of several atypical mycobacteria and BCG, but does not seem to affect resistance to M. tuberculosis.56, 57 In humans, NRAMP1 has been shown in multiple studies to be a risk modifier of TB. This species-dependent permissiveness in mycobacterial replication may be due to dosage and route of pathogen administration in mice that do not accurately mimic the natural infection in humans. Likewise, if resistance to M. tuberculosis is under different genetic controls in mice and humans, it is possible that asthma susceptibility may also be under different control in mice and humans. Another major difference between mouse Nramp1 and human NRAMP1 is the tissue-specific gene expression. In humans, NRAMP1 mRNA expression is more pronounced in the lung than in the spleen and liver,49 whereas in mice, Nramp1 mRNA is expressed strongly in the spleen and liver, with almost no detectable expression in the lung.46, 58, 59, 60 Since M. tuberculosis infection in the mouse manifests itself as progressive lung disease, low or absent Nramp1 expression in the lung of mice coincides with their inability to control M. tuberculosis infection. It is possible that similar, but presently unknown differences, in tissue expression impact on asthma susceptibility in mice and humans. Finally, the mouse findings that provided the rationale for our study used M. vaccae as the mycobacterial stimulant. At present, the effect of NRAMP1 on M. vaccae susceptibility in humans is unknown and it is possible that, like M. tuberculosis, M. vaccae is under different genetic controls in mice and humans.

In conclusion, the results of our study have two implications. First, even in well-developed animal models of complex human diseases such as atopy, the genetic control elements may differ between humans and the model system. Second, it seems unlikely that a single inverse relationship exists between variants that predispose to asthma/atopy and those that predispose to TB. Hence, reduced M. tuberculosis infection may not be the driving force behind increased asthma/atopy prevalence in developed countries, and, if it is, the genetic mechanism is not likely to have included NRAMP1.

Patients and methods


Families are from the Saguenay-Lac-St-Jean region of northeastern Quebec, Canada. The recruitment scheme has been described previously.11 Briefly, probands were recruited if they fulfilled at least two of the following three criteria: (1) a minimum of three clinic visits for acute asthma within 1 year; (2) two or more asthma-related hospital admissions within 1 year; or (3) steroid dependency, as defined by either 6 months of oral, or 1 year of inhaled corticosteroid use. Families were included for study if at least one parent was available for phenotypic assessment, at least one parent was unaffected, and all four grandparents were of French Canadian origin. When possible, grandparents and other relatives were also recruited to the study.

The affection status of all study participants was determined by clinical evaluation and the completion of a standard respiratory questionnaire that was modified to include questions about asthma and atopy severity, family history of asthma and/or atopy, age-of-onset and the presence of other respiratory failure diagnoses.61 We defined participants as asthmatics if (1) a reported history of asthma (questionnaire-based) and a history of physician-diagnosed asthma (past/current) were available, or (2) confirmation of diagnosis by a positive methacholine provocation test was obtained (only on subjects older than 12 years of age). Subjects were deemed atopic if they had at least one positive response (wheel diameter ≥3 mm at 10 min) to skin-prick tests. The family participation rate was approximately 60% and all subjects gave informed consent. A total of 223 independent families (1139 individuals) with family size ranging from 3 to 17 and number of affected family members (including probands) ranging from 1 to 10 were analyzed.

Polymorphism selection and genotyping

Five polymorphisms of the NRAMP1 gene were selected based on their known association with disease. Two of the variants have reference SNP identifiers (rs#) from the NCBI database. In this report, we referred to the common aliases of the variants: 5′(CA)n, 274C>T, 469+14G>C, D543N and 1729+del4.32 Variant 5′(CA)n was genotyped by length polymorphism analysis using ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, CA, USA). Primers for amplifying polymerase chain reaction (PCR) products were designed using Primer3 software ( PCR products of sizes ranging from 168 basepairs (bp) to 182 bp were amplified using primer pair: IndexTerm5′-AACGAGGGGTCTTGGAACTC-3′ and IndexTerm5′-gcctcccaagttagctctga-3′. PCR reactions were carried out in PTC-100® Peltier thermal cyclers (MJ Research, MA, USA) under the following condition: 10 ng of genomic DNA was added to 20 μl reaction mixture containing 1 × PCR buffer, 2.5 mM of MgCl2, 0.5 U of Platinum Taq polymerase (Qiagen, CA, USA), 0.50 mM of dinucleotides and 0.30 μM of primers. PCR was initiated by denaturing the samples at 96°C for 10 min, followed by 30 cycles of denaturation at 96°C for 25 s, annealing at 67°C for 1 min. Final extension was carried out at 72°C for 5 min. Finally, 1 μl of PCR product was mixed with 0.30 μl of formamide and 10 μl of GeneScan™–500 Liz™ Size Standard (Applied Biosystems, CA, USA) before being denatured at 95°C for 5 min and injected into ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, CA, USA). Fluorescence signal was read and analyzed using ABI PRISM® GeneMapper™ Software version 3.5 (Applied Biosystems, CA, USA).

Variants 274C>T and 469+14G>C were genotyped using HEFP™ (Molecular Devices),62 a single-base extension (SBE) fluorescence polarization platform, as previously described.11 Briefly, PCR and SBE primers were designed using the Primer3 software. PCR reactions were carried out using primer set 1 (274C>T): IndexTerm5′-GCCAGCCTGAAGATCTGACT-3′, IndexTerm5′-GGACCCCCTCACTCTACTCC-3′ and set 2 (469+14G>C): IndexTerm5′-ATCGTGGAAGCTGAAAATGG-3′, IndexTerm5′-GCGAGGTCTGCCATCTCTAC-3′. A total of 6 ng of genomic DNA was added to 8 μl reaction mixture containing 2.5 mM of MgCl2, 25 mM of dinucleotides, 0.2 U of HotstartTaq DNA polymerase (Qiagen), and 100 nM of primers. PCR was initiated by denaturing the samples at 94°C for 15 min, followed by 45 cycles of denaturation at 94°C for 30 s, annealing at 56°C (primers specific) for 30 s and extension at 72°C for 30 s. Final extension was done at 72°C for 6 min. PCR products were treated with Exonuclease I and Shrimp Alkaline Phosphatase as recommended by the manufacturer (AcycloPrime-FP SNP Detection Kit, Perkin-Elmer, Wellesley, MA, USA). SBE detection primers used were (274C>T): (sense) IndexTerm5′-GGAAAGCAATGCTCATGAG-3′, (antisense) IndexTerm5′-TTCACGGGGCCTGGCTT-3′, (469+14G>C): (sense) IndexTerm5′-TGGTTCTCCCTGTCCAGG-3′ and (antisense) IndexTerm5′-TAAGGTGAGCTTGGGGG-3′. FP-SBE reactions were performed in one or both orientations as suggested by the manufacturer (AcycloPrime-FP SNP Detection Kit, Perkin-Elmer, Wellesley, MA, USA). After the addition of reading buffer, the plates were read using the Analyst HT® reader (Molecular Devices, CA, USA) as described previously.63

Variants D543N and 1729+55del4 were genotyped by TaqMan assays.64 Each variant was analyzed using two sets of oligonucleotides (external primers and internal probes) designed using the Primer3 software. The internal probes were labelled with fluorescent dyes: TAMRA (6-carboxytetramethyl-rhodamine) at 3′ ends, FAM (6-carboxy-fluorescein) and TET (6-carboxy-4,7,2′,7′-tetrachlorofluorescein) (one per oligonucleotide) at 5′ ends. For variant D543N, primers set IndexTerm5′-CCACCACCACTTCCTGTATG-3′ and IndexTerm5′-CACGTCATACATGCCACTCC-3′ and probes set IndexTerm5′-FAM-CCCTTTCTGGTCCTCTTCAAGGA-TAMRA-3′ and IndexTerm5′-TET-CCCTTTCTGGTTCTCTTCAAGGAGC-TAMRA were used. For variant 1729+55del4, primers set IndexTerm5′-GGGAGTGGCATGTATGACG-3′ and IndexTerm5′-TCTATCCTGCTGCCTGCAC-3′, and probes set IndexTerm5′-FAM-TGGCCTGCTGGATGTGGAGTAMRA and IndexTerm5′-TET-TGACTGGCCTGCTGGAGAGGTAMRA were used. For both variants, 10 ng of genomic DNA were added to a 20 μl reaction mixture containing 1 × PCR buffer, 5.0 mM of MgCl2, 0.2 mM of each nucleotide, 0.5 U of HotstartTaq DNA polymerase (Qiagen), 0.03 μM of probes, and 0.30 mM of primers. PCR was initiated by denaturing the samples at 96°C for 10 min followed by 40 cycles of denaturation at 96°C for 30 s, annealing and extending at 60°C for 1 min. Final extension was carried out at 72°C for 5 min. PCR endpoint fluorescence reading was carried out using ABI PRISM® 7700 Sequence Detector System (Applied Biosystems, CA, USA). The fluorescence intensity was adjusted and recorded using Sequence Detector Software version 1.7 (Applied Systems, CA, USA).

Statistical analysis

Hardy–Weinberg equilibrium was tested in a subset of independent DNA samples (parents of probands) using HAPLOVIEW.65 Allele distribution patterns were assessed by FBAT, (version 1.5).33, 34 This software uses an empirical variance–covariance estimator to account for the possibility of nonindependent allelic transmission to affected sibs.66 Asthma, atopy and IgE level phenotypes were tested separately under additive and dominant genetic models.

Associations between variants were assessed by calculating D′, a measurement of the LD strength67 using HAPLOVIEW.65 Based on the LD strength of variants, haplotypes were inferred and assessed for nonrandom transmission using the ‘hbat’ command of FBAT version 1.5.33, 34 An empirical variance estimator was used.66 Asthma, atopy, and IgE level phenotypes were tested separately under additive and dominant genetic models.

To assess whether the cohort size has sufficient power to detect association between variants and phenotypes, we used Power calculation of the FBAT (PBAT).68, 69 The family design was based on the observed count of nuclear families, according to the number of affected sibs, unaffected sibs, and missing parents. The genetic models considered assumed a constant population prevalence of 0.10, varying susceptibility allele frequencies (q) and varying GAF of the allele GAF, under an additive model for risk. GAF corresponds to a reduction of incidence in the study families when the risk variant is removed, that is, a GAF of 5% indicates that removal of the risk variant would reduce incidence by 5% in the study families. We used values for q ranging from 0.05 to 0.70 and values for GAF ranging from 0.05 to 0.50. For an additive disease model with prevalence at 0.10, the odds ratio for the heterozygotes was calculated for each q and GAF parameter set. The level of significance was set at 0.05.


  1. 1

    Strachan DP . Hay fever, hygiene, and household size. BMJ 1989; 299: 1259–1260.

    CAS  Article  Google Scholar 

  2. 2

    Strachan DP . Family size, infection and atopy: the first decade of the ‘hygiene hypothesis’. Thorax 2000; 55: S2–S10.

    Article  Google Scholar 

  3. 3

    Shirakawa T, Enomoto T, Shimazu S, Hopkin JM . The inverse association between tuberculin responses and atopic disorder. Science 1997; 275: 77–79.

    CAS  Article  Google Scholar 

  4. 4

    Comstock GW, Livesay VT, Woolpert SF . The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99: 131–138.

    CAS  Article  Google Scholar 

  5. 5

    Styblo K . Recent advances in epidemiological research in tuberculosis. Adv Tuberc Res 1980; 20: 1–63.

    CAS  PubMed  Google Scholar 

  6. 6

    Poon A, Schurr E . The NRAMP genes and human susceptibility to common diseases. In: Cellier M, Gros P (eds). The Nramp1 Family. Lands Bioscience: Texas, USA, 2004, pp 29–43.

    Google Scholar 

  7. 7

    Blackwell JM, Jang H-R, White J . Role of Nramp family in pro-inflammatory diseases. In: Cellier M, Gros P (eds). The Nramp1 Family. Lands Bioscience: Texas, USA, 2004, pp 53–64.

    Google Scholar 

  8. 8

    Soo SS, Villarreal-Ramos B, Anjam Khan CM, Hormaeche CE, Blackwell JM . Genetic control of immune response to recombinant antigens carried by an attenuated Salmonella typhimurium vaccine strain: Nramp1 influences T-helper subset responses and protection against leishmanial challenge. Infect Immun 1998; 66: 1910–1917.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9

    Smit JJ, van Loveren H, Hoekstra MO, Nijkamp FP, Bloksma N . Influence of the macrophage bacterial resistance gene, Nramp1 (Slc11a1), on the induction of allergic asthma in the mouse. FASEB J 2003; 17: 958–960.

    CAS  Article  Google Scholar 

  10. 10

    Smit JJ, Van Loveren H, Hoekstra MO, Karimi K, Folkerts G, Nijkamp FP . The Slc11a1 (Nramp1) gene controls efficacy of mycobacterial treatment of allergic asthma. J Immunol 2003; 171: 754–760.

    CAS  Article  Google Scholar 

  11. 11

    Poon AH, Laprise C, Lemire M et al. Association of vitamin d receptor genetic variants with susceptibility to asthma and atopy. Am J Respir Crit Care Med 2004; 170: 967–973.

    Article  Google Scholar 

  12. 12

    Bellamy R . The natural resistance-associated macrophage protein and susceptibility to intracellular pathogens. Microbes Infect 1999; 1: 23–27.

    CAS  Article  Google Scholar 

  13. 13

    Awomoyi AA, Marchant A, Howson JM, McAdam KP, Blackwell JM, Newport MJ . Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis. J Infect Dis 2002; 186: 1808–1814.

    CAS  Article  Google Scholar 

  14. 14

    Gao PS, Fujishima S, Mao XQ et al. Genetic variants of NRAMP1 and active tuberculosis in Japanese populations. International Tuberculosis Genetics Team. Clin Genet 2000; 58: 74–76.

    CAS  Article  Google Scholar 

  15. 15

    Marquet S, Sanchez FO, Arias M et al. Variants of the human NRAMP1 gene and altered human immunodeficiency virus infection susceptibility. J Infect Dis 1999; 180: 1521–1525.

    CAS  Article  Google Scholar 

  16. 16

    Ouchi K, Suzuki Y, Shirakawa T, Kishi F . Polymorphism of SLC11A1 (formerly NRAMP1) gene confers susceptibility to Kawasaki disease. J Infect Dis 2003; 187: 326–329.

    CAS  Article  Google Scholar 

  17. 17

    Shaw MA, Clayton D, Blackwell JM . Analysis of the candidate gene NRAMP1 in the first 61 ARC National Repository families for rheumatoid arthritis. J Rheumatol 1997; 24: 212–214.

    CAS  PubMed  Google Scholar 

  18. 18

    Rodriguez MR, Gonzalez-Escribano MF, Aguilar F, Valenzuela A, Garcia A, Nunez-Roldan A . Association of NRAMP1 promoter gene polymorphism with the susceptibility and radiological severity of rheumatoid arthritis. Tissue Antigens 2002; 59: 311–315.

    CAS  Article  Google Scholar 

  19. 19

    Kojima Y, Kinouchi Y, Takahashi S, Negoro K, Hiwatashi N, Shimosegawa T . Inflammatory bowel disease is associated with a novel promoter polymorphism of natural resistance-associated macrophage protein 1 (NRAMP1) gene. Tissue Antigens 2001; 58: 379–384.

    CAS  Article  Google Scholar 

  20. 20

    Maliarik MJ, Chen KM, Sheffer RG et al. The natural resistance-associated macrophage protein gene in African Americans with sarcoidosis. Am J Respir Cell Mol Biol 2000; 22: 672–675.

    CAS  Article  Google Scholar 

  21. 21

    Boussiotis VA, Tsai EY, Yunis EJ et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000; 105: 1317–1325.

    CAS  Article  Google Scholar 

  22. 22

    Esposito L, Hill NJ, Pritchard LE et al. Genetic analysis of chromosome 2 in type 1 diabetes: analysis of putative loci IDDM7, IDDM12, and IDDM13 and candidate genes NRAMP1 and IA-2 and the interleukin-1 gene cluster. IMDIAB Group. Diabetes 1998; 47: 1797–1799.

    CAS  Article  Google Scholar 

  23. 23

    Kotze MJ, de Villiers JN, Rooney RN et al. Analysis of the NRAMP1 gene implicated in iron transport: association with multiple sclerosis and age effects. Blood Cells Mol Dis 2001; 27: 44–53.

    CAS  Article  Google Scholar 

  24. 24

    Graham AM, Dollinger MM, Howie SE, Harrison DJ . Identification of novel alleles at a polymorphic microsatellite repeat region in the human NRAMP1 gene promoter: analysis of allele frequencies in primary biliary cirrhosis. J Med Genet 2000; 37: 150–152.

    CAS  Article  Google Scholar 

  25. 25

    Cervino AC, Lakiss S, Sow O, Hill AV . Allelic association between the NRAMP1 gene and susceptibility to tuberculosis in Guinea-Conakry. Ann Hum Genet 2000; 64: 507–512.

    CAS  Article  Google Scholar 

  26. 26

    Soborg C, Andersen AB, Madsen HO, Kok-Jensen A, Skinhoj P, Garred P . Natural resistance-associated macrophage protein 1 polymorphisms are associated with microscopy-positive tuberculosis. J Infect Dis 2002; 186: 517–521.

    CAS  Article  Google Scholar 

  27. 27

    Delgado JC, Baena A, Thim S, Goldfeld AE . Ethnic-specific genetic associations with pulmonary tuberculosis. J Infect Dis 2002; 186: 1463–1468.

    CAS  Article  Google Scholar 

  28. 28

    Ryu S, Park YK, Bai GH, Kim SJ, Park SN, Kang S . 3′UTR polymorphisms in the NRAMP1 gene are associated with susceptibility to tuberculosis in Koreans. Int J Tuberc Lung Dis 2000; 4: 577–580.

    CAS  Google Scholar 

  29. 29

    Yang YS, Kim SJ, Kim JW, Koh EM . NRAMP1 gene polymorphisms in patients with rheumatoid arthritis in Koreans. J Korean Med Sci 2000; 15: 83–87.

    CAS  Article  Google Scholar 

  30. 30

    Singal DP, Li J, Zhu Y, Zhang G . NRAMP1 gene polymorphisms in patients with rheumatoid arthritis. Tissue Antigens 2000; 55: 44–47.

    CAS  Article  Google Scholar 

  31. 31

    Meisner SJ, Mucklow S, Warner G, Sow SO, Lienhardt C, Hill AV . Association of NRAMP1 polymorphism with leprosy type but not susceptibility to leprosy per se in west Africans. Am J Trop Med Hyg 2001; 65: 733–735.

    CAS  Article  Google Scholar 

  32. 32

    Liu J, Fujiwara TM, Buu NT et al. Identification of polymorphisms and sequence variants in the human homologue of the mouse natural resistance-associated macrophage protein gene. Am J Hum Genet 1995; 56: 845–853.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33

    Laird NM, Horvath S, Xu X . Implementing a unified approach to family-based tests of association. Genet Epidemiol 2000; 19: S36–S42.

    Article  Google Scholar 

  34. 34

    Horvath S, Xu X, Lake SL, Silverman EK, Weiss ST, Laird NM . Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol 2004; 26: 61–69.

    Article  Google Scholar 

  35. 35

    Gruenheid S, Pinner E, Desjardins M, Gros P . Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited to the membrane of the phagosome. J Exp Med 1997; 185: 717–730.

    CAS  Article  Google Scholar 

  36. 36

    Jabado N, Jankowski A, Dougaparsad S, Picard V, Grinstein S, Gros P . Natural resistance to intracellular infections: natural resistance-associated macrophage protein 1 (Nramp1) functions as a pH-dependent manganese transporter at the phagosomal membrane. J Exp Med 2000; 192: 1237–1248.

    CAS  Article  Google Scholar 

  37. 37

    Plant J, Glynn AA . Genetics of resistance to infection with Salmonella typhimurium in mice. J Infect Dis 1976; 133: 72–78.

    CAS  Article  Google Scholar 

  38. 38

    Bradley DJ . Letter: Genetic control of natural resistance to Leishmania donovani. Nature 1974; 250: 353–354.

    CAS  Article  Google Scholar 

  39. 39

    Skamene E, Gros P, Forget A, Patel PJ, Nesbitt MN . Regulation of resistance to leprosy by chromosome 1 locus in the mouse. Immunogenetics 1984; 19: 117–124.

    CAS  Article  Google Scholar 

  40. 40

    Goto Y, Buschman E, Skamene E . Regulation of host resistance to Mycobacterium intracellulare in vivo and in vitro by the Bcg gene. Immunogenetics 1989; 30: 218–221.

    CAS  Article  Google Scholar 

  41. 41

    Goto Y, Iwakiri A, Shinjo T . Pathogenicities of Mycobacterium intracellulare and M. avium strains to the mice which were isolated from non-tuberculous mycobactriosis patients. Kansenshogaku Zasshi 2002; 76: 425–431.

    Article  Google Scholar 

  42. 42

    Skamene E, Gros P, Forget A, Kongshavn PA, St Charles C, Taylor BA . Genetic regulation of resistance to intracellular pathogens. Nature 1982; 297: 506–509.

    CAS  Article  Google Scholar 

  43. 43

    White JK, Stewart A, Popoff JF, Wilson S, Blackwell JM . Incomplete glycosylation and defective intracellular targeting of mutant solute carrier family 11 member 1 (Slc11a1). Biochem J 2004; 382: 811–819.

    CAS  Article  Google Scholar 

  44. 44

    Malo D, Vogan K, Vidal S et al. Haplotype mapping and sequence analysis of the mouse Nramp gene predict susceptibility to infection with intracellular parasites. Genomics 1994; 23: 51–61.

    CAS  Article  Google Scholar 

  45. 45

    Cellier M, Prive G, Belouchi A et al. Nramp defines a family of membrane proteins. Proc Natl Acad Sci USA 1995; 92: 10089–10093.

    CAS  Article  Google Scholar 

  46. 46

    Govoni G, Canonne-Hergaux F, Pfeifer CG et al. Functional expression of Nramp1 in vitro in the murine macrophage line RAW264.7. Infect Immun 1999; 67: 2225–2232.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. 47

    Forbes JR, Gros P . Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and Nramp2 (Slc11a2) expressed at the plasma membrane. Blood 2003; 102: 1884–1892.

    CAS  Article  Google Scholar 

  48. 48

    Frehel C, Canonne-Hergaux F, Gros P, De Chastellier C . Effect of Nramp1 on bacterial replication and on maturation of Mycobacterium avium-containing phagosomes in bone marrow-derived mouse macrophages. Cell Microbiol 2002; 4: 541–556.

    CAS  Article  Google Scholar 

  49. 49

    Cellier M, Govoni G, Vidal S et al. Human natural resistance-associated macrophage protein: cDNA cloning, chromosomal mapping, genomic organization, and tissue-specific expression. J Exp Med 1994; 180: 1741–1752.

    CAS  Article  Google Scholar 

  50. 50

    Vidal SM, Pinner E, Lepage P, Gauthier S, Gros P . Natural resistance to intracellular infections: Nramp1 encodes a membrane phosphoglycoprotein absent in macrophages from susceptible (Nramp1 D169) mouse strains. J Immunol 1996; 157: 3559–3568.

    CAS  Google Scholar 

  51. 51

    Vidal S, Gros P, Skamene E . Natural resistance to infection with intracellular parasites: molecular genetics identifies Nramp1 as the Bcg/Ity/Lsh locus. J Leukoc Biol 1995; 58: 382–390.

    CAS  Article  Google Scholar 

  52. 52

    Blackwell JM, Barton CH, White JK et al. Genomic organization and sequence of the human NRAMP gene: identification and mapping of a promoter region polymorphism. Mol Med 1995; 1: 194–205.

    CAS  Article  Google Scholar 

  53. 53

    Jabado N, Cuellar-Mata P, Grinstein S, Gros P . Iron chelators modulate the fusogenic properties of Salmonella-containing phagosomes. Proc Natl Acad Sci USA 2003; 100: 6127–6132.

    CAS  Article  Google Scholar 

  54. 54

    Searle S, Blackwell JM . Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility. J Med Genet 1999; 36: 295–299.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. 55

    Zaahl MG, Robson KJ, Warnich L, Kotze MJ . Expression of the SLC11A1 (NRAMP1) 5′-(GT)n repeat: opposite effect in the presence of −237C → T. Blood Cells Mol Dis 2004; 33: 45–50.

    CAS  Article  Google Scholar 

  56. 56

    Medina E, Rogerson BJ, North RJ . The Nramp1 antimicrobial resistance gene segregates independently of resistance to virulent Mycobacterium tuberculosis. Immunology 1996; 88: 479–481.

    CAS  Article  Google Scholar 

  57. 57

    North RJ, LaCourse R, Ryan L, Gros P . Consequence of Nramp1 deletion to Mycobacterium tuberculosis infection in mice. Infect Immun 1999; 67: 5811–5814.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. 58

    Govoni G, Vidal S, Cellier M, Lepage P, Malo D, Gros P . Genomic structure, promoter sequence, and induction of expression of the mouse Nramp1 gene in macrophages. Genomics 1995; 27: 9–19.

    CAS  Article  Google Scholar 

  59. 59

    Vidal SM, Malo D, Vogan K, Skamene E, Gros P . Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell 1993; 73: 469–485.

    CAS  Article  Google Scholar 

  60. 60

    Cellier M, Shustik C, Dalton W et al. Expression of the human NRAMP1 gene in professional primary phagocytes: studies in blood cells and in HL-60 promyelocytic leukemia. J Leukoc Biol 1997; 61: 96–105.

    CAS  Article  Google Scholar 

  61. 61

    Standards for the diagnosis care of patients with chronic obstructive pulmonary disease (COPD) asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987; 136: 225–244.

  62. 62

    Chen X, Levine L, Kwok PY . Fluorescence polarization in homogeneous nucleic acid analysis. Genome Res 1999; 9: 492–498.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63

    Hsu TM, Law SM, Duan S, Neri BP, Kwok PY . Genotyping single-nucleotide polymorphisms by the invader assay with dual-color fluorescence polarization detection. Clin Chem 2001; 47: 1373–1377.

    CAS  PubMed  Google Scholar 

  64. 64

    Lee LG, Connell CR, Bloch W . Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucleic Acids Res 1993; 21: 3761–3766.

    CAS  Article  Google Scholar 

  65. 65

    Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 265–275.

    Google Scholar 

  66. 66

    Lake SL, Blacker D, Laird NM . Family-based tests of association in the presence of linkage. Am J Hum Genet 2000; 67: 1515–1525.

    CAS  Article  Google Scholar 

  67. 67

    Lewontin RC . On measures of gametic disequilibrium. Genetics 1988; 120: 849–852.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. 68

    Lange C, Laird NM . On a general class of conditional tests for family-based association studies in genetics: the asymptotic distribution, the conditional power, and optimality considerations. Genet Epidemiol 2002; 23: 165–180.

    Article  Google Scholar 

  69. 69

    Lange C, DeMeo D, Silverman EK, Weiss ST, Laird NM . Using the noninformative families in family-based association tests: a powerful new testing strategy. Am J Hum Genet 2003; 73: 801–811.

    CAS  Article  Google Scholar 

Download references


We thank all families for their enthusiastic participation in this study. We would like to thank D Gagné and P Bégin for their invaluable participation in the ascertainment of the subjects. We thank Y Renaud, M Girard, and A Verville for technical assistance. We thank A Alcaïs (INSERM U550, Paris) for his comments on statistical analysis. This study was supported by the Canadian Genetic Diseases Network—Network Centres of Excellence (CGDN – NCE). C Laprise is supported by the Fonds pour la recherche en santé du Québec (FRSQ). TJ Hudson is recipient of an Investigator Award from CIHR and a Clinician-Scientist Award in Translational Research from the Burroughs Wellcome Fund. E Schurr is an Investigator of the Canadian Institutes of Health Research.

Author information



Corresponding author

Correspondence to E Schurr.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Poon, A., Laprise, C., Lemire, M. et al. NRAMP1 is not associated with asthma, atopy, and serum immunoglobulin E levels in the French Canadian population. Genes Immun 6, 519–527 (2005).

Download citation


  • genetic predisposition
  • polymorphism
  • natural resistance-associated macrophages protein 1
  • asthma
  • tuberculosis

Further reading


Quick links